NCT05644561 - Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2023

Primary Completion Date

July 15, 2026

Study Completion Date

July 31, 2028

Conditions

Generalized Myasthenia GravisgMG

Interventions

DRUG

Ravulizumab

Ravulizumab will be administered by intravenous (IV) infusion.

Trial Locations (20)

3010

RECRUITING

Research Site, Bern

10126

RECRUITING

Research Site, Torino

11000

RECRUITING

Research Site, Belgrade

11070

RECRUITING

Research Site, Belgrade

13385

RECRUITING

Research Site, Marseille

19104

RECRUITING

Research Site, Philadelphia

20133

RECRUITING

Research Site, Milan

27514

RECRUITING

Research Site, Chapel Hill

28040

WITHDRAWN

Research Site, Madrid

29010

WITHDRAWN

Research Site, Málaga

44308

RECRUITING

Research Site, Akron

60611

RECRUITING

Research Site, Chicago

75571

RECRUITING

Research Site, Paris

76208

RECRUITING

Research Site, Denton

90078

RECRUITING

Research Site, Los Angeles

94143

RECRUITING

Research Site, San Francisco

02115

RECRUITING

Research Site, Boston

00165

RECRUITING

Research Site, Roma

173-0003

RECRUITING

Research Site, Itabashi-ku

2333 ZA

WITHDRAWN

Research Site, Leiden